~~<i id='6F27B8A690'><strike id='6F27B8A690'><tt id='6F27B8A690'><pre id='6F27B8A690'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：Wikipedia 2025-10-04 04:56:38 Page View：34

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BIO selects John Crowley as new CEO
Next article： Dobbs anniversary: the lost opportunity of abortion as health care

knowledge

Trump demands the U.S. pay no more for drugs than other countries … again

EthanMiller/GettyImagesWASHINGTON—FormerPresidentTrumpisbacktocampaigningfortyingMedicaredrugpricest

Stigma and the return of syphilis

AtissuesampleshowingthepresenceofsyphilisSkipVanOrden/CDCviaAPSyphilis,oneoftheoldestinfectionsknown

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Biohaven protein

SpencerPlatt/GettyImagesBiohavenPharmaceuticalssaidWednesdaythatanewtypeofexperimentalmedicinereduce